The 23 references in paper M. GILYAROV Yu., E. KONSTANTINOVA V., М. ГИЛЯРОВ Ю., Е. КОНСТАНТИНОВА В. (2017) “НОВЫЕ ПЕРСПЕКТИВЫ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, ПЕРЕНЕСШИХ СТЕНТИРОВАНИЕ КОРОНАРНЫХ АРТЕРИЙ: ВОЗМОЖНОСТИ ДАБИГАТРАНА // NEW PROSPECTS OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATIO AND CORONARY ARTERY STENTS: DABIGATRAN POTENTIAL” / spz:neicon:aterotromboz:y:2017:i:2:p:21-31

1
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: anupdate of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular ev
(check this in PDF content)
2
Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК, ВНОА, АССХ, 2012. Доступно на: http:// scardio.ru/content/Guidelines/FP_rkj_13.pdf.
(check this in PDF content)
3
Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managingoral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care, 2017, 6: 93-7.
(check this in PDF content)
4
Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J, 2014, 35: 3155-79.
(check this in PDF content)
5
GonzЗlez-Pacheco H, MЗrquez MF, Arias-Mendoza A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol, 2015, 66: 148-154.
(check this in PDF content)
6
Braga CG, Ramos V, Martins J, et al. Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. Rev Port Cardiol,2015, 34(6): 403-10.
(check this in PDF content)
7
Conolly S. J. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet,2006, 367: 1903-1912.
(check this in PDF content)
8
Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest,2010, 137: 263–272.
(check this in PDF content)
9
Chao TF, Liu CJ, Wang KL et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? JACC, 2015, 65: 635–642.
(check this in PDF content)
10
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace,2015, 17(10): 1467-1507.
(check this in PDF content)
11
Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation,2012, 126(10): 1185–93.
(check this in PDF content)
12
Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation,2010, 121: 2067-70.
(check this in PDF content)
13
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation: Task Force for the Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of European Society of Cardiology (ESC). Eur Heart J, 2016, 37: 267-315.
(check this in PDF content)
14
Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet,2013, 381: 1107-15.
(check this in PDF content)
15
Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. JACС, 2013, 62: 981-9.
(check this in PDF content)
16
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-51.
(check this in PDF content)
17
Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation,2013, 127: 634-40.
(check this in PDF content)
18
Cannon CP, Bhatt DL, Oldgren J et al. Dual antitrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med, 2017 Aug 27. doi: 10.1056/NEJMoa1708454.
(check this in PDF content)
19
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost, 2005, 3: 692-4.
(check this in PDF content)
20
Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of CardiologyWorking Group on Thrombosis. Eur Heart J, 2016, 0: 1–11.
(check this in PDF content)
21
Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in in patients with atrial fibrillation: the Euro Heart Survey on atrial fibrillation. Chest,2010, 138: 1093–100.
(check this in PDF content)
22
Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016, 37: 2893-2962.
(check this in PDF content)
23
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice practice guidelines and the Heart Rhythm Society.
(check this in PDF content)